This report aims to elucidate the clinical presentation, diagnostic workup, and therapeutic strategies for JAK2 V617F-positive latent MPN, emphasizing the critical role of molecular testing and thrombosis prevention in such cases. The gene discussed is JAK2; the disease is myeloproliferative disorder.